NYXOAH SA
Last · Brussels€1.072-0.038 (-3.42%)live · yahoo · 5h ago
Vol 373.2K ≈ 400.0K
MA10MA20MA50
Market cap€111.6M101.8M sh
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
€1.072€5.26
Volume373.2Ksession
Issuer
Legal nameNYXOAH SA
HQBelgium (BE)
ListingBE NYXH
ISINBE0974358906
SectorHealthcare
IndustryAdvanced Medical Equipment & Technology
CurrencyEUR
Entity registrylei:5493002O1ESKZ18OXR80
Org IDNYXH
Websitewww.nyxoah.com
Employees154
AddressNyxoah SA Rue Edouard Belin 12 1435, Mont-Saint-Guibert +32 1 045 90 75
| Revenue | €4.3M |
|---|---|
| Operating income | €-45.1M |
| Net income | €-43.2M |
| Free cash flow | €-47.3M |
| Operating margin | -1037.3% |
| Net margin | -993.8% |
| Return on equity | -44.1% |
| Period | 2023 |
Loading chart…
OpenFilings analyst
Our analyst
ANNUAL · 2024-03-21
From latest ANNUAL · 2024-03-21
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -993.8%
- Cash Runway Low — Cash runway ~0.5 years
- Accumulated Deficit High — Accumulated deficit / equity 164%
- Rd Intensity High — R&D/Revenue 612.9%
Upcoming earnings
THU.5NOV
4:40 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.25
Est. revenue
9.9M
Press & signals
- GlobeNewswire
Nyxoah Appoints Liam Kelly as Chief Executive Officer
- GlobeNewswire
Nyxoah Announces Chief Financial Officer Transition
- GlobeNewswire
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
Showing 5 of 101 filings